Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF versus entecavir for bone mineral density reduction after antiviral treatment in chronic hepatitis B
ChiCTR2000034810Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tenofovir alafenamide and entecavir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Estimated glomerular filtration rate and Bone mineral density. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
tenofovir alafenamideentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2000034810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034810.